|
KMID : 0043320200430080765
|
|
Archives of Pharmacal Research
2020 Volume.43 No. 8 p.765 ~ p.772
|
|
|
Hydroxychloroquine and chloroquine: a potential and controversial treatment for COVID-19
|
|
Zou Li
Dai Lijun
Zhang Xingyu
Zhang Zhaohui
Zhang Zhentao
|
|
|
Abstract
|
|
|
|
A novel coronavirus, later named SARS-CoV-2, was first reported in China in December 2019 and subsequently widely identified in the United States, Japan, South Korea, France, India, and other countries. The disease caused by SARS-CoV-2 infection was called COVID-19. The high fatality and morbidity rates of COVID-19 make it the third largest global epidemic in this century. However, there are currently no approved antiviral drugs for the COVID-19 treatment. Recently, two old antimalarial drugs, hydroxychloroquine and chloroquine, have been found to exert anti-SARS-CoV-2 effects both in vitro and in vivo. Preliminary clinical evidence suggests these drugs may have an effect on the treatment of COVID-19. Herein, we review the pharmacokinetics characteristics and antiviral effects of these drugs, in addition to their side effects and clinical evidence of their use for the COVID-19 treatment.
|
|
|
KEYWORD
|
|
|
Hydroxychloroquine, Chloroquine, COVID-19, SARS-CoV-2, Treatment
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|
|